Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14164117 | 1.00 | NFE2L2 (0.51) | NFE2L2ALDH1A1MAPTGAAHTT | |
| SCHEMBL13622799 | 1.00 | NFE2L2 (0.51) | NFE2L2ALDH1A1MAPTGAAHTT | |
| SCHEMBL4816834 | 0.79 | MAPT (0.50) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL4816828 | 0.79 | MAPT (0.50) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL14033785 | 0.78 | MAPT (0.53) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL4912957 | 0.78 | MAPT (0.53) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL28001490 | 0.77 | NFE2L2 (0.44) | NFE2L2ALDH1A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL14277209 | 0.77 | MAPT (0.46) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL31570514 | 0.77 | GAA (0.50) | ALDH1A1MAPTGAAHTTLMNA | |
| SCHEMBL23841243 | 0.77 | MAPT (0.48) | ALDH1A1MAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| CN-1950081-A | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORP (US) | 2007-04-18 | — | — | CN | disclosed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | TRPV1, CNR2, NTRK1 | NFE2L2 3640/4885ALDH1A1 1540/4885MAPT 3232/4885 |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | NFE2L2 3196/4885ALDH1A1 2412/4885MAPT 3260/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | NFE2L2 3204/4885ALDH1A1 2379/4885MAPT 3260/4885 |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | PIGS, GPR35, HRH4 | NFE2L2 2238/4885ALDH1A1 791/4885MAPT 4539/4885 |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | GPR27, GPR88, MUSK | NFE2L2 4300/4885ALDH1A1 1388/4885MAPT 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.